ESMO26: Intismeran sets new benchmark in adjuvant melanoma - Pharmaceutical Technology

One notable finding from the INTerpath-001 trial, for which data was presented at ESMO 2026, was when the benefit appeared. One notable finding from the INTerpath-001 trial, for which data was presented at ESMO 2026, was when the benefit appeared. MSD and Moderna shared the data during the first Presidential Symposium, however it had been made public two days earlier due to a data leak. Credit: Suttipun / Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile,…

Source: Pharmaceutical Technology